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Abstract
Objective. Molecular similarities of grass pollen antigens
have led to the view that cross-reactivity exists within
members of the Pooideae subfamily of grasses. This has
resulted in testing for only the most antigenically represen-
tative member of Pooideae, Timothy grass (Phleum pra-
tense), despite little literature to support the claim that
Phleum is the most representative member or that in vitro
cross-reactivity correlates with in vivo cross-reactivity. The
aim of the study was to determine if patients with allergic
rhinitis symptoms and positive skin prick test results to
meadow fescue (Festuca pratensis) also have positive results
to Timothy grass.
Study Design. Retrospective cross-sectional study.
Setting. Tertiary care center in middle Missouri.
Methods. A retrospective chart review identified patients
12 years old with a diagnosis of allergic rhinitis who under-
went skin prick testing between March 2016 and July 2018,
by using a search with CPT code 95004 (Current Procedural
Terminology). Positive skin prick test results were based on
wheal produced 3 mm than the negative control.
Results. After review of 2182 charts, 1587 patients met cri-
teria to test for Phleum and Festuca. In total, 1239 patients
had a positive result for Phleum or Festuca. Of these, 479
(38.6%) tested positive for Festuca alone, while 342 (27.6%) and
418 (33.7%) tested positive for Phleum alone and Phleum 1
Festuca, respectively.
Conclusion. Clinical cross-reactivity among Pooideae mem-
bers may not be as complete as traditionally thought. P pra-
tense may not be the most antigenically representative
subfamily member, and other grasses may need to be
included in skin prick testing.
Keywords
allergies, allergic rhinitis, skin prick test, immunotherapy,
Pooideae, Phleum, Festuca, grass pollen
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A
llergy, presenting clinically as allergic rhinitis
(AR), affects up to 14.2% of adults in developed
countries and an estimated 500 million people
worldwide.1,2 AR typically presents with sneezing, rhinor-
rhea, and nasal congestion.3 Symptoms result from immedi-
ate responses to antigen, mediated by IgE, and chronic
inflammation via allergen-specific T cells. Skin prick tests
(SPTs) and serum IgE levels, correlated with clinical signs
and symptoms, are used for additional diagnostic workup
for AR. Symptoms caused by AR can cause a considerable
decrease in work productivity and presenteeism, which has
been identified as the largest contributor to the economic
burden of AR.4 The standard medical treatment for AR
includes intranasal steroids, intranasal antihistamines, oral
antihistamines, and nasal saline rinses. However, with aller-
gen avoidance, allergen-specific immunotherapy is the only
treatment modality shown to alter the natural course of
allergic disease.5
Because of this, immunotherapy based on patients’ spe-
cific allergens has become a common treatment for AR.6
When patients experience allergy symptoms to only a few
allergens, the choice of what antigens to include in their
treatment is straightforward. However, when symptoms are
caused due to numerous allergens, as is the case with 60%
to 80% of patients with AR,7 choosing the combination of
antigens to include in their treatment can become compli-
cated.6,8,9 To simplify this, antigens have been extensively
studied to determine the best way to maximize therapy
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while minimizing the number of antigens required to ade-
quately treat patients.
Grass pollens, from allergen groups 1 and 5 in particular,
account for an extensive burden of disease, as an estimated
30% to 70% of patients with AR are sensitized to grass
pollen.10-12 Molecular similarities of grass pollen have led
to suspicions that cross-reactivity exists within members of
similar species.8,13 Of the Pooideae subfamily of grasses,
Phleum pratense has been identified in previous studies as
the most antigenically representative member; thus, its
extract alone has been proposed as being sufficient for pre-
dicting immunotherapy success (marked by an increase in
allergen-specific IgG) from a diagnostic and therapeutic
standpoint.13
A correlation between immunotherapy-induced IgG4
levels and levels of P pratense extract has been shown,
in addition to evidence of T-cell cross-reactivity toward
group 1 allergens.2 Other studies have demonstrated cross-
reactivity among Pooideae species by using 3-dimensional
modeling of grass group 1 allergens, amino acid sequence,
and IgE binding inhibition assays.3,14 These results indicate
that patient IgE may be directed primarily toward common
epitopes, implying that treatment with simply 1 Pooideae
species extract may affect clinical allergic responses from
other members in the subfamily. However, in vitro cross-
reactivity may reflect in vivo allergy testing results to a
lesser degree than previously thought. Indeed, a correlation
between allergy test results and in vitro assays has not been
demonstrated consistently.15 Differences in allergen-specific
T- and B-cell responses have been found, in addition to the
absence of an association between serum IgE responses and
B- and T-cell proliferation.16,17 Thus, despite molecular
similarities supporting cross-reactivity among members of
the Pooideae subfamily, which has led to the common prac-
tice of testing only for P pratense, data are conflicting or
lacking to support the assumption of cross-reactivity in
vivo. Similarly, there is little evidence to support P pratense
being the most representative member of Pooideae.
If P pratense is the most representative of the Pooideae
grass family and cross-reactivity is as extensive as currently
thought, then skin testing with P pratense and a close
member of that subfamily should demonstrate strong con-
cordance between them. With this study, the aim was to
determine if patients with AR symptoms during grass
season with positive SPT result to meadow fescue (Festuca
pratensis) also have a positive SPT result to the previously
identified representative member of the Pooideae subfamily,
Timothy grass (P pratense).
Methods
This study was approved by the University of Missouri
Institutional Review Board (2007840). A retrospective
review of the electronic health record at a single tertiary
care center from March 1, 2016, to July 31, 2018, was per-
formed to identify patients aged 12 years with a diagnosis
of AR with symptoms during grass season who underwent
skin prick testing, by using a search of CPT code 95004
(Current Procedural Terminology). All patients were tested
with Multi-Test II devices (Lincoln Diagnostics) with
panels including allergenic extracts (from Stallergenes-
Greer and ALK) specific for the central Missouri area,
including Phleum as the representative of the Pooideae sub-
family; however, Festuca grasses have become more promi-
nent in the surrounding areas. Festuca was added to testing
panels on a trial basis. Positive results on skin prick testing
to Phleum, Festuca, or both were based on recorded wheal
size 3 mm when compared with the negative control prick
test (50% glycerin), given that it was a satisfactory test with
the positive histamine control prick test 7 mm when com-
pared with the negative glycerin control.
Results
Overall, 2182 patient charts were identified and reviewed. It
was determined that 1587 records met criteria and included
testing for Phleum and Festuca. Of these patients, 1239 had
at least 1 positive test result to Phleum or Festuca. Phleum-
only positive cases included 342 (27.6%) patients, while a
surprising 479 (38.6%) were positive to Festuca only. It
was noted that 418 (33.7%) patients were positive to both
Phleum and Festuca on skin prick testing (Table 1).
Among the patients who had a positive SPT result to
Phleum, 45% had a positive result only to Phleum, while
55% had positive results to Phleum and Festuca. For
patients with a positive test result to Festuca, interestingly
53.4% had a positive result to Festuca only, as compared
with 46.6% who had a positive result to Festuca and
Phleum.
To determine if these numbers of Festuca-only results
were statistically significant, the expected Festuca count
was calculated (Figure 1). If a Phleum-positive test is com-
pletely predictive of a Festuca-positive test as previous liter-
ature reports, then a Festuca-only test result happens under
1 of 2 scenarios: (1) the patient is truly sensitized, with
false-negative Phleum and true-positive Festuca test results,
or (2) the patient is not sensitized, with true-negative
Phleum and false-positive Festuca test results. Table 2
shows the expected number and 95% CIs of Fescue-only
test results that should occur if the Phleum-positive test is
completely predictive of a Festuca-positive result.
Table 1. Skin Prick Test Results (N = 1587).a
Positive result
Tested for Phleum and Festuca 1239 (78.1)b
Positive for
Phleum only 342 (27.6)
Festuca only 479 (38.6)
Phleum1Festuca 418 (33.7)
aResults are presented as No. (%).




The expected count and 95% CI of Festuca-only test
results were estimated empirically in a simulation study per-
formed with R version 3.6.0 (R Foundation for Statistical
Computing). In this study, the expected number of Festuca-
only test results was assumed to depend on the underlying
prevalence of fescue allergy in the test population and on
the reliability of the allergy tests. In the simulations, we
assumed a 30%-70% prevalence of Festuca allergy in the
test population, based on the literature, in accordance with
estimates for the proportion of individuals with an allergy
who present with symptoms.10,11 In addition, we conserva-
tively assumed the tests to have a 2% false-negative rate
and 5% false-positive rate according to materials from
the test company (Lincoln Diagnostics, Inc). Using these
assumptions, we simulated 10,000 studies of 1587 individu-
als similar to the original study. The mean and 95%
quantiles of the simulations were compared with the actual
number of Festuca-only cases observed in the original
study. The maximum number of expected Festuca-only
results was 62 (95% CI, 47-78). According to this analysis,
it is statistically impossible to obtain the results of 479
patients with Festuca-only SPT results based solely on
chance.
Discussion
Unexpectedly, a higher percentage of patients showed a
positive test result to Festuca only when compared with
Phleum only. Historically, Phleum has been identified as
the representative member of the Pooideae subfamily.13
Recommendations have been made to test for only this
member of Pooideae to identify all sensitizations to antigens
within this subfamily. However, these results suggest that
Phleum may not be the most antigenically representative
within Pooideae, as there was such a high percentage of
patients who were sensitized to Festuca only.
A much higher-than-expected 53.4% of patients with
Festuca positivity were not sensitized to Phleum. Based on
previous in vitro data, this result should not have been seen.
If a Phleum-positive test were completely predictive of a
Festuca-positive test, as historically thought, the percentage
of Festuca-only cases should have been considerably less.
In vivo reactivity of members of the Pooideae subfamily
has the potential to be very different when compared with
in vitro reactivity.
If Festuca is not tested, it is possible that almost 40% of
patients with grass pollen allergy symptoms will not have
their antigen identified. Missing an antigen that causes sig-
nificant symptoms can significantly affect the treatment of
allergy patients, including frustration, continued AR symp-
toms, and noncompliance. With a goal of maximizing ther-
apy while minimizing antigens in immunotherapy vials,
educated choices must be made about which antigens to test
Table 2. Expected Festuca-Only Test Results Based on the Prevalence
of Grass Allergy.a






aTest results depend on the prevalence of an allergy in the test population
and the reliability of the tests.
bExpected count if the Phleum test is completely predictive of a Festuca-pos-
itive result. This is derived from the sum of the estimation for the false
negatives of Phleum and the false positives of Festuca, according to these for-
mulas: false negatives = population 3 prevalence of allergy 3 false-negative
test result 3 true-positive test result; false positives = population 3 (1 2












30% 40% 50% 60% 70%
Expected "Festuca only" count 95% lower limit 95% Upper limit
Figure 1. Expected number of Festuca-only test results based on the prevalence of grass allergy in the tested population, according to the
sum of the false positives for Festuca and false negatives for Phleum.
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to ultimately include in the vial. However, 40% of patients
is a substantial amount that cannot be ignored.
These results join a growing body of literature that sug-
gests that cross-reactivity may not be as straightforward as
previously thought, including a combination of specific and
cross-reactive T-cell and antibody responses.18 Additionally,
this study adds to the literature suggesting that the most
effective method to induce tolerance with immunotherapy is
to include the specific allergens causing clinical symptoms
rather than the antigen of a member of the same subfam-
ily.18,19 Indeed, testing for Festuca is not unnecessary and
can have significant clinical implications.
It is important to note that this study has some limita-
tions. It is based on the population of patients in mid-
Missouri. Festuca is actually an invasive species in this
region and quite prevalent.20 It has the potential to over-
grow, causing increased exposure in patients in this region
when compared with other areas of the United States and
the world. Additionally, this study is a retrospective review
and does not allow for follow-up of symptoms based on
immunotherapy treatment developed from positive SPT
results. Prospective studies are needed in multiple patient
populations to determine the in vivo results of skin prick
testing, as well as the clinical symptoms and treatment, of
patients who are sensitized to members of the Pooideae
subfamily.
Conclusions
The cross-reactivity among Pooideae members may not be
as complete as traditionally thought. P pratense may not be
the most antigenically representative Pooideae subfamily
member. Additional grass pollens, other than Phleum alone,
may need to be included in skin prick testing to avoid miss-
ing clinically symptomatic sensitivities in patients with AR
due to grass pollen. Additional prospective studies are
required to accurately determine in vivo data about potential
cross-reactivity among members of the Pooideae subfamily.
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